Obayashi to Acquire Multiplex in $526M Expansion Deal 
US-Iran De-Escalation Shifts Washington’s Focus to AI Regulation and Crypto Legislation 
Trump Administration Delays DeepSeek and CXMT Trade Blacklist Designations Amid U.S.-China Tensions 
Carro Expands Into Australia With Acquisition of Used-Car Platform CarPlace 
BHP Shares Fall as Jansen Potash Project Costs Surge 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
SoftBank Shares Drop as OpenAI Losses and Rising Costs Spark Investor Concerns 
Jio IPO Filing Nears as Reliance Targets $4 Billion Market Debut 
Kingboard Holdings Shares Surge After HK$11.77 Billion Block Trade to Expand PCB and AI Supply Chain Business 
Saudi Aramco Explores Sulphur Business Stake Sale to Raise Billions 
SpaceX Stock Slides After IPO Rally as Valuation Concerns Grow 
Hyundai to Acquire SoftBank’s Remaining Boston Dynamics Stake for $325 Million 
US Raises Concerns Over Possible ASML EUV Machine Transfer to China 
Meta Seeks Legal Shield From Child-Harm Lawsuits Amid KOSA Talks 
GM and Lockheed Martin Partner to Strengthen U.S. Defense Manufacturing Capacity 
G7 Explores AI Access Deal With U.S. Amid Anthropic Restrictions 
WILMINGTON, Del., Jan. 15, 2016 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A.:
- Do you, or did you, own shares of XBiotech Inc. (NASDAQ:XBIT)?
- Did you purchase your shares pursuant and/or traceable to the April 15, 2015 initial public offering, or between April 15, 2015 and November 23, 2015, inclusive?
- Did you lose money in your investment?
Rigrodsky & Long, P.A. reminds shareholders of XBiotech Inc. (“XBiotech” or the “Company”) (NASDAQ:XBIT) of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company. A complaint was filed in the United States District Court for the Western District of Texas on behalf of all persons or entities that purchased the common stock of XBiotech between April 15, 2015 and November 23, 2015, inclusive (the “Class Period”) alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its officers. A separate complaint has been filed in the Superior Court of the State of California on behalf of all persons or entities that acquired XBiotech shares pursuant or traceable to its initial public offering (“IPO”) commenced on or about April 15, 2015, alleging violations of the Securities Exchange Act of 1933 against the Company and certain of its officers.
If you wish to serve as lead plaintiff, you must move the Court no later than February 1, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Any member of the proposed class may move the court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.
If you purchased shares of XBiotech in the April 15, 2015 offering, or during the period April 15, 2015 and November 23, 2015, inclusive, and wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact Timothy J. MacFall, Esquire or Peter Allocco of Rigrodsky & Long, P.A., 2 Righter Parkway, Suite 120, Wilmington, DE 19803 at (888) 969-4242; by e-mail to [email protected]; or at: http://rigrodskylong.com/investigations/xbiotech-inc-xbit.
Attorney advertising. Prior results do not guarantee a similar outcome.
CONTACT: Rigrodsky & Long, P.A. Timothy J. MacFall, Esquire Peter Allocco (888) 969-4242 (516) 683-3516 Fax: (302) 654-7530 [email protected] http://www.rigrodskylong.com
